Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Immunomedics Inc (NASDAQ:IMMU)

6.88
Delayed Data
As of Mar 24
 +0.25 / +3.77%
Today’s Change
1.95
Today|||52-Week Range
7.05
+87.47%
Year-to-Date
Immunomedics, Mylan Lead Biotech Movers
Mar 24 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close6.63
Today’s open6.98
Day’s range6.65 - 7.05
Volume4,926,327
Average volume (3 months)3,196,954
Market cap$729.8M
Dividend yield--
Data as of 4:14pm ET, 03/24/2017

Growth & Valuation

Earnings growth (last year)-21.57%
Earnings growth (this year)+2.42%
Earnings growth (next 5 years)+20.00%
Revenue growth (last year)-42.81%
P/E ratioNM
Price/Sales68.00
Price/Book--

Competitors

 Today’s
change
Today’s
% change
QDELQuidel Corp+0.16+0.76%
--Quidel Corp+0.40+2.07%
ALRPRBAlere Inc+7.50+2.33%
VIVOMeridian Bioscience ...+0.15+1.16%
Data as of 3:59pm ET, 03/24/2017

Financials

Next reporting dateMay 10, 2017
EPS forecast (this quarter)-$0.13
Annual revenue (last year)$3.2M
Annual profit (last year)-$59.0M
Net profit margin-1,825.93%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, Chief Scientific &
Patent Officer
David M. Goldenberg
President, Chief Executive Officer &
Director
Cynthia L. Sullivan
Corporate headquarters
Morris Plains, New Jersey

Forecasts


Search for Jobs